ALK FISH Assays for Non-small Cell Lung Cancer Treatment Selection: Scoring Issues and Probe Design
|
|
- Basil Cook
- 8 years ago
- Views:
Transcription
1 ALK FISH Assays for Non-small Cell Lung Cancer Treatment Selection: Scoring Issues and Probe Design Helen J. Lawce and Susan Olson Abstract Lung cancer is becoming more treatable with new pharmaceuticals. There is a growing interest in FISH testing to determine which drugs to use on lung cancer patients for the best results, with a concurrent need for laboratories to provide ALK FISH testing for nonsmall-cell lung cancer. However, the test has some unique difficulties and requires a great deal of experience to interpret in some cases. A three-color probe may help make the ALK FISH test more reliable. Glossary Adenocarcinoma: malignant tumor of a gland Carcinoma: a cancer arising in the epithelial tissue of the skin or of the lining of the internal organs Companion diagnostic: a diagnostic test linked to a specific, known therapeutic drug to provide information to enable treatment decisions Large-cell carcinoma: a microscopically identified variant of certain cancers, for example lung cancers, in which the abnormal cells are particularly large Squamous-cell carcinoma: a carcinoma that arises from squamous epithelium tinib : denotes a tyrosine kinase inhibitor Lung cancer kills 1.4 million people worldwide with 160,000 of these deaths occurring in the United States. It is the leading cause of cancer deaths in the United States, exceeding the mortality of breast, prostate, and colon cancer combined. Tobacco smoking causes the majority of lung cancers. However, there are a growing number of lung cancers in individuals who have never smoked ( lifetime never smokers ), with a frequency of approximately 10-15% of all lung cancers. Lung carcinoma in nonsmokers is usually attributed to genetic factors, aging, radon gas, asbestos, and/or air pollution. Most primary lung cancers are carcinomas that are derived from epithelial cells, and the main categories are small-cell lung carcinoma ( oat cell cancer ) and non-small-cell lung carcinoma (NSCLC). The three types of NSCLC are adenocarcinoma, squamous-cell carcinoma, and large-cell carcinoma. Each type of lung cancer grows and spreads differently and may be treated differently. For the last decade, tyrosine kinase inhibitors (TKIs) have been used to treat late stage lung cancers. Tyrosine kinases (TKs) are enzymes that are responsible for the activation of signal transduction through phosphorylation of various proteins. Tyrosine kinases (TKs) include the BCR/ABL fusion protein in CML, for which the TKI imatinib (Gleevec) was developed. Shortly after the FDA approved Gleevec, the TKIs gefitinib (Iressa), and erlotinib (Tarceva) were developed against carcinogenic mutations leading to overexpression of the TK EGFR (epidermal growth factor receptor, also called erbb1) for the treatment of advanced lung tumors. ALK (anaplastic lymphoma kinase) is a TK that was originally discovered because of its involvement in a translocation t(2;5) (ALK/NPM [nucleophosmin] fusion) in anaplastic large cell lymphoma. The ALK gene is rearranged, mutated or amplified in several types of tumor besides lymphoma including neuroblastoma and NSCLC. In 2007, Soda et al. reported that an inversion on the chromosome 2 short arm (Figure 1) caused a fusion of ALK with EML4 (echinoderm microtubule-associated protein-like 4) inhibiting apoptosis and inducing cell proliferation. Recent studies have indicated that the ALK-EML4 gene fusion is present in 2-7% of all NSCLCs in the United States, with a higher frequency in nonsmoking patients. Patients with this gene fusion are typically younger non-smokers who do not have mutations in either the EGFR gene or in the K-Ras gene. Lung cancer patients whose tumors carry the ALK rearrangement respond well to the TKI crizotinib (Xalkori). The recently published College of American Pathologists guidelines recommend fluorescent in situ hybridization (FISH) testing for ALK rearrangements in adenocarcinomas and mixed lung cancers with an adenocarcinoma component, but not for other types of lung cancer such as squamous, small cell, or large cell carcinoma with no evidence for adenocarcinoma differentiation (Lindeman et al., 2013). The requirement for this new assay to determine treatment has translated into a growing need for FISH testing. Often, EGFR mutation testing is being done at the same time or before the FISH testing and so the CAP guidelines cover both tests. The FDA has approved the Abbott Molecular Laboratories ALK Break Apart FISH assay as a companion diagnostic for selection of patients to be treated with the FDA-approved ALK TKI, crizotinib. It consists of a Spectrum Orange-labeled 300-kb probe on the telomeric side of ALK and a Spectrum Greenlabeled 442-kb probe on the centromeric side (Figure 2). If the ALK region is not rearranged, it will appear as a fused orange and green signal. Due to the high ploidy of many lung tumors, there may be multiple fused signals in a nucleus with no rearrangements (Figure 3a). If the ALK region has been translocated or inverted, it will appear as separated orange and green signals separated by more than two signal widths apart (Figures 3b,c). Often there 66
2 2p 42,250,020 42,413,192 29,269,144 29,997,936 2p with location of EML4 and ALK relative to each other a) 2p b) Inversion Fusion of EML4/ALK: a. Wild type b. Inversion with fusion of ALK/EML4 Figure 1. Diagram of the EML4/ALK inversion rearrangement on chromosome 2. Multiple different EML4-ALK translocation variants have since been identified that contain various truncations of EML4 but always contain the tyrosine kinase domain of ALK, starting at exon 20. The most common (~70%) translocations in NSCLC involve EML4 exon 13 (variant 1) or EML4 exon 6 (variant 3a/b; 3b contains an additional 33-bp due to alternative splicing). Reprinted by permission from Atlas Genet Cytogenet Oncol Haematol July 2009; Perner S, Wilbertz T, Stiedl AC, Rubin MA. EML4 is loss of the green signal resulting in a single orange signal instead of the classic split orange and green signals, and these variant patterns are considered positive because the orange signal is on the kinase coding side of the ALK gene. The native fused orange/green signal may be missing but presence of an orange and green signal is enough to call a cell positive for a rearrangement (Figure 3d). For ALK rearrangements, because there are several partners besides EML4, a break-apart FISH probe design is the strategy of choice. Other partners for ALK include KIF5B (kinesin family member 5B on chromosome 10) and TFG (TRK-fused gene, chromosome 3). Because the ALK/EML4 rearrangement is often caused by a small paracentric inversion of 2p21/2p23, the split signals do not always move very far apart, making the interpretation of the FISH more difficult than other break-apart probe rearrangements. Further confounding the interpretation is that tumors may be multiclonal, heterogeneous, and mixed with stromal elements so that the numbers of cells exhibiting a clear split signal can be proportionally small. Depending upon multiple factors, both preanalytical (necrosis, fixation times, age of slides or tissue blocks) and analytical (e.g., enzymatic overdigestion), signals from tumors without rearrangements can separate almost as much as those harboring an inversion. An unusual feature of this rearrangement is the variability of the EML4 breakpoint, with at least 11 variants (Figure 4). The variant breakpoints can cause differences in the distance that the orange and green signals separate from each other (Wallandar et al., 2012). Wallander et al. (2012) hybridized ALK to tumors with different EML4 variants detected with multiple methods including PCR, and they report that for EML4 variant 3a/b, there was concordance 67
3 Telomere 2p23 Region Centromere LSI ALK Dual Color, Break Apart Rearrangement Probe 2 Figure 2. The Abbott Molecular Laboratories FDA approved ALK break-apart probe design, reproduced by permission of Abbott Molecular Laboratories. Figure 3. ALK patterns in adenocarcinoma of lung. A. No rearrangement of ALK but extra signals for ALK. B. ALK is split (positive cells) but signals do not separate very far since the rearrangement, a paracentric inversion, is within the same arm of chromosome 2. C. ALK is split (positive cells) and signals are widely spaced. Most likely these cells are carrying an interchromosomal exchange. D. ALK is split, leaving only a normal fusion with a single orange signal (left) or no normal fusion with only an orange and green signal (right). Both are considered positive for a scorable rearrangement by FDA guidelines. 68
4 variant 1 EML4 ALK variant 2 variant 3a variant 3b variant 4a variant 4b linker of 11 bp variant 5a variant 5b Intron 19 of ALK Figure 4. Some of the 11 (and growing in number) known EML4 breakpoint variations and fusion isoforms (numbers = exon number). Variant 1: exon 1-13 (EML4) + exon (ALK) Variant 2: exon 1-20 (EML4) + exon (ALK) Variant 3a: exon 1-6a (EML4) + exon (ALK) Variant 3b: exon 1-6b (EML4) + exon (ALK) Variant 4a : exon 15 (EML4) + exon (ALK) Variant 4b : exon 14 (EML4) + linker of 11bp + exon (ALK) Variant 5a : exon 2 (EML4) + exon (ALK) Variant 5b : exon 2 (EML4) + intron 19 (ALK) + exon (ALK) Reprinted by permission from Atlas Genet Cytogenet Oncol Haematol July 2009; Perner S, Wilbertz T, Stiedl AC, Rubin MA. EML4 between scorers on the positive samples, but for variant 1, only 1 tumor out of 9 was scored positive by all three readers using a 40% cutoff. Variant 1 is the most common (Perner et al., 2009). Therefore, it can be difficult to score ALK FISH assays, and there is need for experience with many normal and abnormal samples to gain familiarity with and accuracy in scoring them. The CAP guidelines suggest that a pathologist not only mark the tumor area for the technologist to score, but that they either do the scoring or check the slides after the technologist scores them. No matter who scores the slides, the recommendations suggest that the best strategy is to have two scorers check each sample, and that they are trained in the appearance of tumor nuclei so they do not inadvertently score normal stroma, lymphocytes or neutrophils. Again, it is not unusual for two scorers to find discordant results due to the difficulties inherent in the test (Wallender et al., 2012). The original trials in which ALK FISH was shown to predict treatment response determined that the cutoff for interphase positive FISH findings for split signals was 15% or more (Camidge et al., 2010; Rodig et al., 2009), and that cutoff is still being used in most laboratories. The original researchers did not address the findings of the single orange signal patterns with loss of the green. However, the Abbott insert does include the variant signal patterns and uses the 15% cutoff value for all positive findings (split orange and green or loss of green with extra orange signals). For cases of ALK interchromosomal translocations, the split signals are easily scored due to the distance between the chromosomes involved. For inversions, where artifactual split signals are difficult to distinguish from true split signals, the FDA method encourages the use of the cutoff value of 15% to interpret the findings, with the artifactual split signals falling below 15% 69
5 2p D ALK ~729kb D25213 SHGC EML4 ~160kb SHGC ~410kb ~493kb ~623kb ~437kb Figure 5. Cymogen Dx 4 color ALK-EML4 probe design, reprinted by permission. The ALK-EML4 del-tect Four Color direct labeled FISH probe: the two probes flanking the ALK gene are a telomeric CYMO-AQUA ALK probe ~410 kb in size and a centromeric CYMO-ORANGE probe ~493 kb in size. The two probes flanking the EML4 gene are a telomeric CYMO-GREEN probe ~623 kb in size and a centromeric CYMO-RED probe ~437 kb in size. Figure 6. Cymogen Dx 4 color ALK-EML4 probe hybridized to normal tonsil cell. in this paradigm. Nonetheless, even with two or more scorers, the findings can appear equivocal. In response to the inherent difficulties scoring ALK breakapart probes CymoGen Dx (New Windsor, New York) developed a unique four-color probe design for the EML4/ALK rearrangement. Their probe consists of two colors flanking each gene (Figures 5, 6). The ALK is aqua, and the ALK (centromeric) is orange, so if the ALK (aqua) is rearranged with a different chromosome, it will simply separate from the orange, leaving the EML4 fusion intact. If there has been an inversion, the aqua ALK will form a fusion with either the green or the red that flank the EML4, and sometimes with both the green and the red signals, depending on which EML4 breakpoint is involved (Figures 7). A single ALK aqua is also considered a positive finding with the four-color probe, just as it would be in the Abbott probe design with the single ALK signal in orange. This probe design is elegant and informative. However, with four colors, it is difficult to interpret against a polyploid background with overlapping signals and truncation artifact. For a day-to-day clinical test, it may be more feasible to create a combination of the two approaches, reducing the design to three colors. In order to make a standard, red or orange/green break-apart probe more sensitive for the inversion rearrangement, it seems reasonable to add an aqua probe that spans the EML4 gene region. For equivocal split signals, the aqua can be used to determine a true split signal pattern. If it splits and partially fuses with the ALK (orange), it would be consistent with an inversion. If the EML4 aqua did not split or juxtapose with the ALK signal, it would indicate that no inversion had taken place. There is a three-color break-apart commercial probe available with this design including an EML4-spanning aqua component from the German company Zytovision. Ideally, the aqua component of the probe could be made available as an additive to the standard two-color probe set from Abbott Molecular Laboratories for investigating equivocal cases. Such a design would make the ALK assay for NSCLC much more sensitive and specific, and if it were available for the FDA-approved probe it would allow for better accuracy in choosing treatment regimens using this companion diagnostic. Because of the unusual characteristics of the ALK- EML4 rearrangement with the complications of potentially heterogeneous/necrotic/truncated/mucinous tumors that may 70
6 Figure 7. Cells from the same tumor hybridized with: A. the FDA approved Abbott Molecular Laboratory ALK probe and B. the 4-color Cymogen ALK-EML4 probe set. have faint or loose signals, the two-color ALK break-apart probe set has a fair probability of a false positive or negative result. It is critical to be sure we are doing our best for these patients and the health care community. References Camidge DR, Kono SA, Flacco A, Tan AC, Doebele RC, Zhou Q, Crino L, Franklin WA, Varella-Garcia M. Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment. Clin Cancer Res. 2010; 16(22): Lindeman, N, Cagle, P, Beasley, M, Dhananjay, A, Dacic, S, Giaccone, G, Jenkins, R, Kwaitkowski, D, Saldivar, J, Squire, J, Thunnissen, E, Ladanyi, M. Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors. Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. Arch Pathol Lab Med, February 12, Perner S, Wilbertz T, Stiedl AC, Rubin MA. EML4 (echinoderm microtubule associated protein like 4). Atlas Genet Cytogenet Oncol Haematol. July EML4ID44353ch2p21.html Rodig SJ, Mino-Kenudson M, Dacic S, Yeap BY, Shaw A, Barletta JA, Stubbs H, Law K, Lindeman N, Mark E, Janne PA, Lynch T, Johnson BE, Iafarate AJ, Chirieac LR. Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. Clin Cancer Res. 2009; 15(16): Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, Fujiwara S, Watanabe H, Kurashina K, Hatanaka H, Bando M, Ohno S, Ishikawa Y, Aburatani H, Niki T, Sohara Y, Sugiyama Y, Mano H. Nature Aug 2;448(7153): Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, Fujiwara S, Watanabe H, Kurashina K, Hatanaka H, Bando M, Ohno S, Ishikawa Y, Aburatani H, Wallander ML, Geiersbach KB, Tripp SR, Layfield LJ. Comparison of reverse transcription-polymerase chain reaction, immunohistochemistry, and fluorescence in situ hybridization methodologies for detection of echinoderm microtubule-associated proteinlike 4-anaplastic lymphoma kinase fusion-positive non-small cell lung carcinoma: implications for optimal clinical testing. Arch Pathol Lab Med Jul; 136(7): Wallander ML, Geiersbach KB, Tripp SR, Layfield LJ. Comparison of reverse transcription-polymerase chain reaction, immunohistochemistry, and fluorescence in situ hybridization methodologies for detection of echinoderm microtubule-associated proteinlike 4-anaplastic lymphoma kinase fusion-positive non-small cell lung carcinoma: implications for optimal clinical testing. Arch Pathol Lab Med Jul;136(7): Helen J. Lawce and Susan Olson Oregon Health & Science University Knight Diagnostic Cytogenetic Laboratories lawceh@ohsu.edu 71
Corporate Medical Policy
Corporate Medical Policy Molecular Analysis for Targeted Therapy for Non-Small Cell Lung File Name: Origination: Last CAP Review: Next CAP Review: Last Review: molecular_analysis_for_targeted_therapy_for_non_small_cell_lung_cancer
More informationSuccesses and Limitations of Targeted Cancer Therapy in Lung Cancer
Successes and Limitations of Targeted Cancer Therapy in Lung Cancer Kenichi Suda a, b Tetsuya Mitsudomi a a Division of Thoracic Surgery, Department of Surgery, Kinki University Faculty of Medicine, Osaka-Sayama,
More informationTargeted Therapies in Lung Cancer
Targeted Therapies in Lung Cancer I Edited by: Simona Carnio Thoracic Oncology Division - St Luigi Hospital Orbassano (TO) - Italy Silvia Novello Department of Oncology - University of Torino - Italy Why
More informationHER2 Testing in Breast Cancer
HER2 Testing in Breast Cancer GAIL H. VANCE, M.D. AGT MEETING JUNE 13, 2014 LOUISVILLE, KENTUCKY No Conflict of Interest to Report Human Epidermal Growth Factor Receptor 2-HER2 Human epidermal growth factor
More informationEARLY ONLINE RELEASE
EARLY ONLINE RELEASE Note: This article was posted on the Archives Web site as an Early Online Release. Early Online Release articles have been peer reviewed, copyedited, and reviewed by the authors. Additional
More informationNon-Small Cell Lung Cancer
Non-Small Cell Lung Cancer in East tasia Chia-Chi (Josh) Lin, MD, PhD 林 家 齊 Director of Phase I Center, e Department of Oncology, National Taiwan University Hospital Clinical Associate Professor, Department
More informationALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials)
ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials) 3 Integrated Trials Testing Targeted Therapy in Early Stage Lung Cancer Part of NCI s Precision Medicine Effort in
More informationtargeted cancer therapy
LUNG CANCER TREATMENTS What you need to know about... targeted cancer therapy foreword About LUNGevity LUNGevity is the largest national lung cancer-focused nonprofit, changing outcomes for people with
More informationThe following information is only meant for people who have been diagnosed with advanced non-small cell
Important information for people with advanced non-small cell lung cancer The following information is only meant for people who have been diagnosed with advanced non-small cell lung cancer (NSCLC). NSCLC
More informationtargeted therapy a guide for the patient
targeted therapy FOR LUNG CANCER a guide for the patient TABLE OF CONTENTS lung cancer basics... 2-3 Gene changes... 4-5 Testing... 7-8 Targeted therapy... 9-11 Drugs Targeting EGFR... 12 Drugs Targeting
More informationThe EGFR mutation and precision therapy for lung cancer
for lung cancer Outcomes in advanced lung cancer have seen meaningful improvement in the past decade thanks to new precision drug therapies. Because tumors usually develop resistance to the drugs, scientists
More informationPharmacogenomic markers in EGFR-targeted therapy of lung cancer
Pharmacogenomic markers in EGFR-targeted therapy of lung cancer Rafal Dziadziuszko, MD, PhD University of Colorado Cancer Center, Aurora, CO, USA Medical University of Gdansk, Poland EMEA Workshop on Biomarkers,
More informationA disease of populations of cells that live, divide, invade and spread without regard to normal limits
1 Targeted Cancer Therapies Mark McKeage Medical Oncology Specialist Professor in Clinical Pharmacology 2 Cancer Definition- A disease of populations of cells that live, divide, invade and spread without
More informationChanging Paradigms for evaluating costs and benefits of drug treatments. Deven Chauhan Health Economist Office of Health Economics London, UK
Changing Paradigms for evaluating costs and benefits of drug treatments Deven Chauhan Health Economist Office of Health Economics London, UK What do we mean by changing paradigms? Elevating pharmaceutical
More informationALK Testing in Lung Cancer
Edited by Ming SOUND Tsao, MD, FRCPC Fred R. Hirsch, MD, PhD Yasushi Yatabe, MD, PhD IASLC Atl as of ALK Testing in Lung Cancer international Association for the Study of Lung Cancer IASLC Atlas of ALK
More informationEGFR gene mutations Ex 19 Ex 21 Paez et al, Science 2004
Evolution of knowledge in NSCLC Pao and Girard, Lancet Oncology 2011 Fattori da considerare nella scelta terapeutica del NSCLC nel 2012 Stadio di malattia PS Età Comorbidità Compliance e desiderio del
More informationUnderstanding series. new. directions. 1-800-298-2436 LungCancerAlliance.org. A guide for the patient
Understanding series LUNG CANCER: new treatment directions 1-800-298-2436 LungCancerAlliance.org A guide for the patient TABLE OF CONTENTS What s New in lung cancer? Advancements...4 Changes in genes that
More informationWhat is New in Oncology. Michael J Messino, MD Cancer Care of WNC An affiliate of Mission hospitals
What is New in Oncology Michael J Messino, MD Cancer Care of WNC An affiliate of Mission hospitals Personalized Medicine Personalized Genomics Genomic Medicine Precision Medicine Definition Application
More informationMarch 19, 2014. Dear Dr. Duvall, Dr. Hambrick, and Ms. Smith,
Dr. Daniel Duvall, Medical Officer Center for Medicare, Hospital and Ambulatory Policy Group Centers for Medicare and Medicaid Services 7500 Security Boulevard Baltimore, Maryland 21244 Dr. Edith Hambrick,
More informationNon Small Cell Lung Cancer: Scientific Discoveries and the Pursuit of Progress
Non Small Cell Lung Cancer: Scientific Discoveries and the Pursuit of Progress Lung Cancer Accounts for 14% of All New Cancer Diagnoses in the United States 1 Lung cancer is the second most common malignancy
More informationAdvancing Personalized Therapy for Advanced Non-Small Cell Lung Cancer
GUIDING THE WAY White Paper Advancing Personalized Therapy for Advanced Non-Small Cell Lung Cancer is a serum proteomic test for patients with advanced non-small cell lung cancer that helps healthcare
More informationGenomic Medicine The Future of Cancer Care. Shayma Master Kazmi, M.D. Medical Oncology/Hematology Cancer Treatment Centers of America
Genomic Medicine The Future of Cancer Care Shayma Master Kazmi, M.D. Medical Oncology/Hematology Cancer Treatment Centers of America Personalized Medicine Personalized health care is a broad term for interventions
More informationALK+ lung cancer and the Blood-Brain Barrier (BBB) A concise guide
ALK+ lung cancer and the Blood-Brain Barrier (BBB) A concise guide Contents Section Page number Section 1: Lung cancer and ALK+ NSCLC 3 Section 2: The Blood-Brain Barrier (BBB): What and why? 4 Section
More informationLung cancer was the most commonly diagnosed cancer
Advances in Treatment of Lung Cancer With Targeted Therapy Philip T. Cagle, MD; Lucian R. Chirieac, MD, PhD N Context. Ongoing preclinical investigations and clinical trials involving new targeted therapies
More informationYOUR LUNG CANCER PATHOLOGY REPORT
UNDERSTANDING YOUR LUNG CANCER PATHOLOGY REPORT 1-800-298-2436 LungCancerAlliance.org A GUIDE FOR THE PATIENT 1 CONTENTS What is a Pathology Report?...3 The Basics...4 Sections of a Pathology Report...7
More informationTrends in Molecular target therapy for Lung Cancer
QUARTERLY REVIEW No.38 / January 2011 1 Trends in Molecular target therapy for Lung Cancer Hiromi OMOE Life Science Research Unit 1 Introduction Lung cancer, a refractory cancer, is the most common cause
More informationNuevas tecnologías basadas en biomarcadores para oncología
Nuevas tecnologías basadas en biomarcadores para oncología Simposio ASEBIO 14 de marzo 2013, PCB Jose Jimeno, MD, PhD Co-Founder / Vice Chairman Pangaea Biotech SL Barcelona, Spain PANGAEA BIOTECH BUSINESS
More informationBreast and Lung Cancer Biomarker Research at ASCO: Changing Treatment Patterns
July 2013 Edition Vol. 7, Issue 7 Breast and Lung Cancer Biomarker Research at ASCO: Changing Treatment Patterns By Julie Katz, MPH, MPhil Biomarkers played a prominent role in the research presented in
More informationNon-small Cell Lung Cancer
Non-small Cell Lung Cancer Eva Szabo, MD Division of Cancer Prevention, NCI TRACO 11-2-15 Outline US Lung Cancer Statistics Tobacco use and lung cancer Risk Factors Tobacco, tobacco, tobacco (85% lung
More informationLung Cancer: More than meets the eye
Lung Cancer Education Program November 23, 2013 Lung Cancer: More than meets the eye Shantanu Banerji MD, FRCPC Presenter Disclosure Faculty: Shantanu Banerji Relationships with commercial interests: Grants/Research
More informationMEDICAL POLICY EFFECTIVE DATE: 12/20/07 REVISED DATE: 12/18/08, 12/17/09, 02/17/11, 12/15/11, 12/20/12, 12/19/13, 02/19/15
MEDICAL POLICY SUBJECT: GENOTYPING - EPIDERMAL GROWTH PAGE: 1 OF: 6 If a product excludes coverage for a service, it is not covered, and medical policy criteria do not apply. If a commercial product, including
More informationHER2 FISH pharmdx. Assay Kit
PATHOLOGY HER2 FISH pharmdx Assay Kit HER2 FISH pharmdx Clarity You Can Count On Reliable Results at a Glance The robust HER2 FISH pharmdx assay offers bright and distinct signals for easy and fast reading
More informationApplications of comprehensive clinical genomic analysis in solid tumors: obstacles and opportunities
Applications of comprehensive clinical genomic analysis in solid tumors: obstacles and opportunities Vincent A. Miller, M.D. Foundation Medicine, Inc. AACR Annual Meeting 2012 Current Concepts session
More informationClinical development of AZD9291 in non-small cell lung cancer
Clinical development of AZD9291 in non-small cell lung cancer Rachael Lawrance (AstraZeneca) PSI One Day Meeting: The Innovative, Challenging and Diversified World of Respiratory Disease 13 Nov 2015 Overview
More informationPreparation of a phosphotyrosinylated protein standard for 2D gel western blotting
Preparation of a phosphotyrosinylated protein standard for 2D gel western blotting Nancy Kendrick, Matt Hoelter, Andrew Koll, and Jon Johansen Kendrick Labs, Inc, Madison, WI www.kendricklabs.com Introduction
More informationName of Policy: Molecular Analysis for Targeted Therapy of Non-Small-Cell Lung Cancer (NSCLC)
Name of Policy: Molecular Analysis for Targeted Therapy of Non-Small-Cell Lung Cancer (NSCLC) Policy #: 468 Latest Review Date: October 2015 Category: Laboratory Policy Grade: B Background/Definitions:
More informationThe last decade has witnessed the dramatic coming
Lung Cancer Pathology Changing paradigm and priorities Ming-Sound Tsao, MD, FRCPC Abstract The last decade has witnessed the dramatic coming of age of targeted therapy in lung cancer. Several new targeted
More informationCancer. 9p21.3 deletion. t(12;21) t(15;17)
CANCER FISH PROBES INDIVIDUAL AND PANEL S Acute Lymphoblastic Leukemia (ALL) ALL FISH Panel (includes all probes below) 8010 LSI MYB/CEP6 LSI p16 (CDKN2A) LSI BCR/ABL with ASS LSI ETV6 (TEL)/AML1 (RUNX1)
More informationTargeted Therapy What the Surgeon Needs to Know
Targeted Therapy What the Surgeon Needs to Know AATS Focus in Thoracic Surgery 2014 David R. Jones, M.D. Professor & Chief, Thoracic Surgery Memorial Sloan Kettering Cancer Center I have no disclosures
More informationLung cancer is not just one disease. There are two main types of lung cancer:
1. What is lung cancer? 2. How common is lung cancer? 3. What are the risk factors for lung cancer? 4. What are the signs and symptoms of lung cancer? 5. How is lung cancer diagnosed? 6. What are the available
More informationAgenda. Regulatory Success. Regulatory Success. Regulatory Success. Antiquated Reimbursement Methodology. Coding Transparency Initiatives
VALUE-BASED REIMBURSEMENT FOR PERSONALIZED MEDICINE: WHERE DO WE STAND? overview US health care value-based purchasing reforms, explore implications for diagnostics and personalized medicines Michael Longacre,
More informationCorso Integrato di Clinica Medica ONCOLOGIA MEDICA AA 2010-2011 LUNG CANCER. VI. THERAPY. III. TARGETED THERAPY FOR NON SMALL CELL LUNG CANCER Prof.
Corso Integrato di Clinica Medica ONCOLOGIA MEDICA AA 2010-2011 LUNG CANCER. VI. THERAPY. III. TARGETED THERAPY FOR NON SMALL CELL LUNG CANCER Prof. Alberto Riccardi Targeted therapies. I. Signaling pathways
More informationPATHOLOGY. HercepTestTM. Product Information
PATHOLOGY HercepTestTM Product Information CLINICAL TRIALS HercepTest The First and Foremost Dako s pharmdx HercepTest was the first FDA-approved assay developed exclusively to aid physicians in identifying
More informationLung Cancer Research: From Prevention to Cure!
Lung Cancer Research: From Prevention to Cure! Ravi Salgia, M.D, Ph.D Associate Professor of Medicine Director, Thoracic Oncology Research Program Department of Medicine Section of Hematology/Oncology
More informationProtocol. Molecular Analysis for Targeted Therapy of Non-Small- Cell Lung Cancer
Molecular Analysis for Targeted Therapy of Non-Small- Cell Lung (20445) (Formerly Epidermal Growth Factor Receptor [EGFR] Mutation Analysis for Patients with Non-Small Cell Lung [NSCLC] and KRAS Mutation
More informationIndividualizing Your Lung Cancer Care: Informing Decisions Through Biomarker Testing
Individualizing Your Lung Cancer Care: Informing Decisions Through Biomarker Testing These Are Hopeful Times for Lung Cancer Survivors When people first learn they have cancer, they are often afraid. But
More informationNational Medical Policy
National Medical Policy Subject: Policy Number: Molecular Tumor Markers for Non-Small Cell Lung Cancer (NSCLC) NMP206 Effective Date*: November 2010 Update: June 2015 This National Medical Policy is subject
More informationtreatments) worked by killing cancerous cells using chemo or radiotherapy. While these techniques can
Shristi Pandey Genomics and Medicine Winter 2011 Prof. Doug Brutlag Chronic Myeloid Leukemia: A look into how genomics is changing the way we treat Cancer. Until the late 1990s, nearly all treatment methods
More informationLaboratory Testing for Her2 Status in Breast Cancer
Laboratory Testing for Her2 Status in Breast Cancer Katherine Geiersbach, M.D. Assistant Professor, Department of Pathology May 28, 2015 Overview Clinical relevance of Her2 status for treatment of breast
More informationEmerging Drug List GEFITINIB
Generic (Trade Name): Manufacturer: Gefitinib (Iressa ) formerly referred to as ZD1839 AstraZeneca NO. 52 JANUARY 2004 Indication: Current Regulatory Status: Description: Current Treatment: Cost: Evidence:
More informationPOLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT VARIATIONS DISCLAIMER CODING INFORMATION REFERENCES POLICY HISTORY
Original Issue Date (Created): 9/1/2011 Most Recent Review Date (Revised): 1/27/2015 Effective Date: 11/2/2015 POLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT VARIATIONS
More informationCHAPTER 2: UNDERSTANDING CANCER
CHAPTER 2: UNDERSTANDING CANCER INTRODUCTION We are witnessing an era of great discovery in the field of cancer research. New insights into the causes and development of cancer are emerging. These discoveries
More informationEvaluating the Efficiency of Targeted Designs for Randomized Clinical Trials
Vol. 0, 6759 6763, October 5, 004 Clinical Cancer Research 6759 Perspective Evaluating the Efficiency of Targeted Designs for Randomized Clinical Trials Richard Simon and Aboubakar Maitournam Biometric
More informationAppendix 2 Molecular Biology Core Curriculum. Websites and Other Resources
Appendix 2 Molecular Biology Core Curriculum Websites and Other Resources Chapter 1 - The Molecular Basis of Cancer 1. Inside Cancer http://www.insidecancer.org/ From the Dolan DNA Learning Center Cold
More informationKRAS Mutation Analysis in Non-Small Cell Lung Cancer (NSCLC) Original Policy Date
MP 2.04.43 KRAS Mutation Analysis in Non-Small Cell Lung Cancer (NSCLC) Medical Policy Section Medicine Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Reviewed with literature search/12:2013
More informationProposal for Tyrosine Kinase Inhibitors for Non Small Cell Lung Cancer
31 May 2012 Proposal for Tyrosine Kinase Inhibitors for Non Small Cell Lung Cancer PHARMAC is seeking feedback on a proposal to: fund gefitinib (Iressa) as a first line treatment for patients with locally
More informationLung Cancer. Advances in Lung Cancer Treatment
Lung Cancer Advances in Lung Cancer Treatment Treatment for lung cancer is changing rapidly. There are new therapies that target specific molecular changes that drive the growth and spread of the lung
More informationClinical Outcomes of Thoracic Radiotherapy for Locally Advanced NSCLC with EGFR Mutations or EML4-ALK Rearrangement
Clinical Outcomes of Thoracic Radiotherapy for Locally Advanced NSCLC with EGFR Mutations or EML4-ALK Rearrangement HIDETOSHI HAYASHI 1, ISAMU OKAMOTO 1, HIDEHARU KIMURA 2, KAZUKO SAKAI 2, YASUMASA NISHIMURA
More informationCHROMOSOMES Dr. Fern Tsien, Dept. of Genetics, LSUHSC, NO, LA
CHROMOSOMES Dr. Fern Tsien, Dept. of Genetics, LSUHSC, NO, LA Cytogenetics is the study of chromosomes and their structure, inheritance, and abnormalities. Chromosome abnormalities occur in approximately:
More informationMedical Policy Manual. Date of Origin: August 2010. Topic: Molecular Analysis for Targeted Therapy of Non- Small Cell Lung Cancer (NSCLC)
Medical Policy Manual Topic: Molecular Analysis for Targeted Therapy of Non- Small Cell Lung Cancer (NSCLC) Section: Genetic Testing Policy No: 56 Date of Origin: August 2010 Last Reviewed Date: December
More informationTargeted agents in lung cancer: EGFR TKI and beyond
Targeted agents in lung cancer: EGFR TKI and beyond David CL Lam, MBBS, PhD, MD, FCCP, FACP, FRCP, FAPSR Clinical Assistant Professor Department of Medicine University of Hong Kong 13 Nov, 2014 The Changing
More informationCancerTREATMENT NGS+ NSCLC Summary Report Page 1 of 7 PATIENT SPECIMEN PHYSICIAN
Page 1 of 7 POSITIVE TEST RESULTS Biomarker Result DETECTED NEGATIVE TEST RESULTS FDA Approved Therapies Targeting Molecular Pathway TEST DESCRIPTION: CancerTREATMENT NGS+ uses Next Generation Sequencing
More informationMolecular Stratification of Cancer in the
Molecular Stratification of Cancer in the Clinical Setting David Gonzalez de Castro Molecular Diagnostics NHS FT and The Institute of Cancer Research, London, UK 1 2 The complexity of human cancer genomes
More informationFARMACI PERSONALIZZATI PER
ISTITUTO NAZIONALE PER LO STUDIO E LA CURA DEI TUMORI FONDAZIONE G. Pascale NAPOLI SC Biologia Cellulare e Bioterapie CENTRO RICERCHE ONCOLOGICHE MERCOGLIANO (AV) Laboratorio di Farmacogenomica FARMACI
More informationLung Cancer Awareness 2009
Lung Cancer Awareness 2009 Guest Expert: Thomas, Jr., MD Director, Yale Cancer Center; Physicianin-Chief, Smilow Cancer Hospital at Yale-New Haven www.wnpr.org www.yalecancercenter.org Welcome to Yale
More informationREFERENCE CODE GDHC212DFR PUBLICAT ION DATE JUNE 2013 GSK1572932A (NON-SMALL CELL LUNG CANCER) FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC212DFR PUBLICAT ION DATE JUNE 2013 GSK1572932A (NON-SMALL CELL LUNG CANCER) GSK1572932A (NON-SMALL CELL LUNG CANCER) - Executive Summary GSK1572932A (MAGE-A3): Key Metrics in NSCLC Markets
More informationMEDICAL POLICY EFFECTIVE DATE: 07/20/06 REVISED DATE: 10/18/07, 10/23/08, 10/29/09, 10/28/10, 03/17/11, 02/16/12, 01/17/13, 01/16/14
MEDICAL POLICY SUBJECT: HER-2 TESTING IN INVASIVE BREAST OR PAGE: 1 OF: 6 If the member's subscriber contract excludes coverage for a specific service it is not covered under that contract. In such cases,
More informationFuture Directions in Clinical Research. Karen Kelly, MD Associate Director for Clinical Research UC Davis Cancer Center
Future Directions in Clinical Research Karen Kelly, MD Associate Director for Clinical Research UC Davis Cancer Center Outline 1. Status of Cancer Treatment 2. Overview of Clinical Research at UCDCC 3.
More informationThe following chapter is called "Preimplantation Genetic Diagnosis (PGD)".
Slide 1 Welcome to chapter 9. The following chapter is called "Preimplantation Genetic Diagnosis (PGD)". The author is Dr. Maria Lalioti. Slide 2 The learning objectives of this chapter are: To learn the
More informationA Cost Effective Way to De Risk Biomarker Clinical Trials: Early Development Considerations
A Cost Effective Way to De Risk Biomarker Clinical Trials: Early Development Considerations Ce3, Inc. and Insight Genetics, Inc. Oncology Forum July 15, 2015 Agenda Introductions Definitions Regulations
More informationSeattle. Case Presentations. Case 1. 76 year old female with a history of breast cancer 12 years ago. Now presents with a pleural effusion.
Seattle Montreal IAP September 2006 Case Presentations Allen M. Gown, M.D. Medical Director and Chief Pathologist PhenoPath Laboratories Clinical Professor of Pathology University of British Columbia Case
More informationBreakthrough Lung Cancer Treatment Approved Webcast September 9, 2011 Renato Martins, M.D., M.P.H. Introduction
Breakthrough Lung Cancer Treatment Approved Webcast September 9, 2011 Renato Martins, M.D., M.P.H. Please remember the opinions expressed on Patient Power are not necessarily the views of Seattle Cancer
More informationSpread the Word, Once and for All. The Lung Cancer Prevention & Detection Kit
Spread the Word, Once and for All The Lung Cancer Prevention & Detection Kit About Spread the Word, Once and for All The NFCR Lung Cancer Prevention and Detection Kit Lung cancer is the leading killer
More informationHarmesh Naik, MD. Hope Cancer Clinic HOW DO I MANAGE STAGE 4 NSCLC IN 2012: STATE OF THE ART
Harmesh Naik, MD. Hope Cancer Clinic HOW DO I MANAGE STAGE 4 NSCLC IN 2012: STATE OF THE ART Goals Discuss treatment options for stage 4 lung cancer: New and old Discuss new developments in personalized
More informationThe lungs What is lung cancer? How common is it? Risks & symptoms Diagnosis & treatment options
Why We re Here The lungs What is lung cancer? How common is it? Risks & symptoms Diagnosis & treatment options What Are Lungs? What Do They Do? 1 Located in the chest Allow you to breathe Provide oxygen
More informationLung cancer remains the leading cause of cancer-related death in the. Evolving Treatment Paradigms in Non-Small Cell Lung Cancer
PRINTER-FRIENDLY VERSION AT CLINICALONCOLOGY.COM Evolving Treatment Paradigms in Non-Small Cell Lung Cancer KATHRYN F. MILEHAM, MD Staff Oncologist HEATHER D. BROOKS, MD Staff Oncologist EDWARD S. KIM,
More informationCML. cure. A Patient s Guide. Molecular Biology Diagnosis Stem Cell Transplant Monitoring New Drugs Questions to Ask and More
A Patient s Guide to CML Molecular Biology Diagnosis Stem Cell Transplant Monitoring New Drugs Questions to Ask and More cure C a n c e r U p d at e s, R e s e a r c h & E d u c at i o n Based on science,
More informationName of Policy: Proteomic Testing for Targeted Therapy in Non-Small Cell Lung Cancer
Name of Policy: Proteomic Testing for Targeted Therapy in Non-Small Cell Lung Cancer Policy #: 570 Latest Review Date: October 2015 Category: Laboratory Policy Grade: B Background/Definitions: As a general
More informationMonoclonal Antibodies in Cancer. Ralph Schwall, PhD Associate Director, Translational Oncology Genentech, Inc.
Monoclonal Antibodies in Cancer Ralph Schwall, PhD Associate Director, Translational Oncology Genentech, Inc. Disclaimer I had nothing to do with Herceptin Using lessons learned in new antibody projects
More informationSomething Old, Something New.
Something Old, Something New. Michelle A. Fajardo, D.O. Loma Linda University Medical Center Clinical Presentation 6 year old boy, presented with hematuria Renal mass demonstrated by ultrasound & CT scan
More informationLung cancer is the leading cause of cancer-related death in the United
Evolving Treatment Paradigms in Non-Small Cell Lung Cancer MARGARET E. M. VAN METER, MD Medical Oncology Fellow Division of Cancer Medicine The University of Texas M.D. Anderson Cancer Center Houston,
More informationMolekylært målrettet medicinsk kræftbehandling for klinikere principper og metoder
Molekylært målrettet medicinsk kræftbehandling for klinikere principper og metoder Professor Claus Lindbjerg Andersen Department of Molecular Medicine (MOMA) Aarhus University hospital Outline The central
More informationMUTATION, DNA REPAIR AND CANCER
MUTATION, DNA REPAIR AND CANCER 1 Mutation A heritable change in the genetic material Essential to the continuity of life Source of variation for natural selection New mutations are more likely to be harmful
More informationDevelopments in Biomarker Identification and Validation for Lung Cancer
Developments in Biomarker Identification and Validation for Lung Cancer Alexandre Passioukov, MD, PhD Alexandre.Passioukov@eortc.be Contents Introduction Lung cancer pathogenesis NSCLC treatment options
More informationPublished Ahead of Print on April 11, 2011 as 10.1200/JCO.2010.31.8923. J Clin Oncol 29. 2011 by American Society of Clinical Oncology
Published Ahead of Print on April 11, 2011 as 10.1200/JCO.2010.31.8923 The latest version is at http://jco.ascopubs.org/cgi/doi/10.1200/jco.2010.31.8923 JOURNAL OF CLINICAL ONCOLOGY A S C O S P E C I A
More informationThe CML Guide Information for Patients and Caregivers
The CML Guide Information for Patients and Caregivers LEUKEMIA LYMPHOMA CHRONIC MYELOGENOUS LEUKEMIA MYELOMA Printing of this publication made possible by a grant from A Message from John Walter President
More informationFuture Oncology: Technology, Products, Market and Service Opportunities
Brochure More information from http://www.researchandmarkets.com/reports/296370/ Future Oncology: Technology, Products, Market and Service Opportunities Description: Future Oncology is an analytical newsletter
More informationCancer Treatment Reviews
Cancer Treatment Reviews 38 (2012) 416 430 Contents lists available at SciVerse ScienceDirect Cancer Treatment Reviews journal homepage: www.elsevierhealth.com/journals/ctrv Antitumour Treatment EGFR-mutated
More informationHER2 Status: What is the Difference Between Breast and Gastric Cancer?
Ask the Experts HER2 Status: What is the Difference Between Breast and Gastric Cancer? Bharat Jasani MBChB, PhD, FRCPath Marco Novelli MBChB, PhD, FRCPath Josef Rüschoff, MD Robert Y. Osamura, MD, FIAC
More informationEvolving Treatment Paradigms in Non-Small Cell Lung Cancer
PRINTER-FRIENDLY VERSION AT PHARMACYPRACTICE NEWS.COM Evolving Treatment Paradigms in Non-Small Cell Lung Cancer CALEB T. CHU, MD, MPH Postdoctoral Fellow Department of Thoracic/Head and Neck Medical Oncology
More informationLung Cancer Genomics and Patient Individualization
Lung Cancer Genomics and Patient Individualization Ming Sound Tsao, MD, FRCPC Qasim Choksi Chair in Lung Cancer Translational Research University Health Network OCI/PMH Leading Causes of Deaths (WHO) In
More informationImproving EGFR kinase inhibitor design for the targeted treatment of lung cancer.
Improving EGFR kinase inhibitor design for the targeted treatment of lung cancer. Shannon Tarby, Earl Benjamin III, and Ellis Benjamin Department of Chemistry, Richard Stockton College of New Jersey, 101
More informationEpidermal Growth Factor Receptor Mutations in Patients with Non Small Cell Lung Cancer
Review Epidermal Growth Factor Receptor Mutations in Patients with Non Small Cell Lung Cancer Bruce E. Johnson and Pasi A. Jänne Lowe Center for Thoracic Oncology, Department of Medical Oncology, Dana-Farber
More informationYour Guide to the Breast Cancer Pathology Report
Your Guide to the Breast Cancer Pathology Report Developed for you by Breastcancer.org is a nonprofit organization dedicated to providing education and information on breast health and breast cancer. The
More informationKeywords: Lung Cancer, EGFR kinase, Inflammation
Improving EGFR kinase inhibitor design for the targeted treatment of lung cancer. Shannon Tarby, Earl Benjamin III, and Ellis Benjamin Department of Chemistry, Richard Stockton College of New Jersey, 101
More informationNuove mutazioni nella leucemia mielomonoci/ca cronica
Nuove mutazioni nella leucemia mielomonoci/ca cronica Firenze 31 marzo 2011 DANIEL A CILLONI UNIVERSITA DEGLI STUDI DI TORINO DIPARTIMENTO DI SCIENZE CLINICHE E BIOLOGICHE c Ros1 Human Human ortholog of
More informationA leader in the development and application of information technology to prevent and treat disease.
A leader in the development and application of information technology to prevent and treat disease. About MOLECULAR HEALTH Molecular Health was founded in 2004 with the vision of changing healthcare. Today
More information( targeted therapy ) ( oncogenesis ) ( epidermal. growth factor receptor tyrosine kinase inhibitor EGFR-TKI ) ( epidermal growth
2008 19 8-13 growth factor receptor tyrosine kinase inhibitor EGFR-TKI ) ( targeted therapy ) ( oncogenesis ) ( epidermal factor receptor monoclonal antibody EGFR-moAb ) growth factor monoclonal antibody
More informationWhite paper Evaluation of BRAF (V600E) Mutation by Immunohistochemical Staining with anti-braf V600E (VE1) Antibody: A Comparison with Sanger
White paper Evaluation of BRAF (V600E) Mutation by Immunohistochemical Staining with anti-braf V600E (VE1) Antibody: A Comparison with Sanger Sequencing 2 Evaluation of BRAF (V600E) Mutation by Immunohistochemical
More informationLung Cancer Research: From Prevention to Cure (Video Transcript)
Lung Cancer Research: From Prevention to Cure (Video Transcript) To view the accompanying video of this transcript and to download a PDF of the physician's slide presentation, visit: http://www.uchospitals.edu/specialties/cancer/lung/video/index.html
More information